



\\PDPDesktop\ODM\iManage;367672;1  
NSP\MKM\JJT\TAD\jam(cmb)  
02/05/03

1653 \$  
PATENT APPLICATION  
DOCKET NO.: 2932.1008-000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
FEB 14 2003  
TECH CENTER 1800/2900

#24

Applicants: Jordan J.N. Tang and Arun K. Ghosh  
Application No.: 09/603,713 Group Art Unit: 1653  
Filed: June 27, 2000 Examiner: Abdel A. Mohamed  
Confirmation No.: 4604  
Title: Inhibitors of Memapsin 2 and Use Thereof

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202	
on <u>2-7-03</u>	<u>Jane Morgan</u>
Date	Signature
<u>JANE MORGAN</u>	
Typed or printed name of person signing certificate	

SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
P.O. Box 2327  
Arlington, VA 22202

Sir:

This Sixth Supplemental Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

☐ under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

☒ under 37 CFR 1.97(c) together with either:

☐ a Statement under 37 CFR 1.97(e), as checked below, or

☒ a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:

☐ a Statement under 37 CFR 1.97(e), as checked below, and

☐ a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

☐ under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

02/12/2003 MCHHMM1 00000050 09603713

180.00 \$P

01 FC:1806

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references (AF2-AH2, AM4, AY11-AZ11 and AR12-AS12) are enclosed.
- ☐ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☒ The listed reference (AU) was cited in the enclosed Annex to the Invitation to Pay Additional Fees (Form PCT/ISA/206) in a related foreign application PCT/US01/50826. The remaining references listed in the Annex to the Invitation to Pay Additional Fees have been cited in previously filed Information Disclosure Statements.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
  - ☐ the explanation provided in the Specification.
  - ☐ submission of the enclosed International Search Report.
  - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
  - ☐ the enclosed English language abstract.

[ X ] Applicant requests that the following non-published pending applications be considered:

Examiner's  
Initials

\_\_\_\_ U.S. Patent Application No. 10/281,092, by Arun K. Ghosh, Jordan J. N. Tang, Geoffrey Bilcer, Wanpin Chang, Lin Hong, Gerald Koelsch, Jeff Loy and Robert T. Turner III, filed October 23, 2002, Docket No.: 2932.1001-004

\_\_\_\_ U.S. Patent Application No. 10/279,748, by Wanpin Chang, Jordan Tang, Gerald Koelsch, Lin Hong, Jeff Loy, Arun K. Ghosh, Robert T. Turner, III and Geoffrey Bilcer, filed October 22, 2002, Docket No.: 2932.1001-003

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_\_  
Examiner

\_\_\_\_\_  
Date

[ X ] A copy of each of the above-cited applications, including the current claims, is enclosed.

[ ] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

[ X ] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

[ ] Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By

  
Mary K. Murray

Registration No.: 47,813

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: February 7, 2003

**COPY**

PATENT APPLICATION  
DOCKET NO.: 2932.1008-000



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
FEB 14 2003  
TECH CENTER 1600/2900

Applicants: Jordan J.N. Tang and Arun K. Ghosh  
Application No.: 09/603,713 Group Art Unit: 1653  
Filed: June 27, 2000 Examiner: Abdel A. Mohamed  
Confirmation No.: 4604  
Title: Inhibitors of Memapsin 2 and Use Thereof

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202	
on	<u>2-7-03</u>
Date	Signature
	<u>JANE MORGAN</u>
Typed or printed name of person signing certificate	

SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
P.O. Box 2327  
Arlington, VA 22202

Sir:

This Sixth Supplemental Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)
- ☐ under 37 CFR 1.97(b), or  
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☒ under 37 CFR 1.97(c) together with either:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, or
- ☒ a \$180.00 fee under 37 CFR 1.17(p), or  
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, and
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):  
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.  
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
  - ☒ Copies of the cited references (AF2-AH2, AM4, AY11-AZ11 and AR12-AS12) are enclosed.
  - ☐ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
  - ☒ The listed reference (AU) was cited in the enclosed Annex to the Invitation to Pay Additional Fees (Form PCT/ISA/206) in a related foreign application PCT/US01/50826. The remaining references listed in the Annex to the Invitation to Pay Additional Fees have been cited in previously filed Information Disclosure Statements.
  - ☐ The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:
    - ☐ the explanation provided on the attached sheet.
    - ☐ the explanation provided in the Specification.
    - ☐ submission of the enclosed International Search Report.
    - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
    - ☐ the enclosed English language abstract.

[ X ] Applicant requests that the following non-published pending applications be considered:

Examiner's  
Initials

\_\_\_\_ U.S. Patent Application No. 10/281,092, by Arun K. Ghosh, Jordan J. N. Tang, Geoffrey Bilcer, Wanpin Chang, Lin Hong, Gerald Koelsch, Jeff Loy and Robert T. Turner III, filed October 23, 2002, Docket No.: 2932.1001-004

\_\_\_\_ U.S. Patent Application No. 10/279,748, by Wanpin Chang, Jordan Tang, Gerald Koelsch, Lin Hong, Jeff Loy, Arun K. Ghosh, Robert T. Turner, III and Geoffrey Bilcer, filed October 22, 2002, Docket No.: 2932.1001-003

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_  
Examiner

\_\_\_\_  
Date

[ X ] A copy of each of the above-cited applications, including the current claims, is enclosed.

[ ] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

[ X ] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

[ ] Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By

  
Mary K. Murray

Registration No.: 47,813

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: February 7, 2003

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
2932.1008-000

APPLICATION NO.  
09/603,713

**SUPPLEMENTAL INFORMATION DISCLOSURE  
CITATION  
IN AN APPLICATION**

APPLICANT  
Jordan J.N. Tang and Arun K. Ghosh

FEB 11 2003

February 5, 2003

FILING DATE  
June 27, 2000

CONFIRMATION NO.  
4604

GROUP  
1653

(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

EXA M- INER INI- TIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
	AF2	US2002/0111365 A1	August 15, 2002	Wolfe et al.
	AG2	US2002/0159991 A1	October 31, 2002	Cordell et al.
	AH2	US2002/0157122 A1	October 24, 2002	Wong et al.

**RECEIVED**  
FEB 14 2003  
TECH CENTER 1800/2900

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AM4	WO 02/47466 A2	20/06/02	PCT			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AY11	Dorrell, S., "Untangling Alzheimer's disease with $\beta$ -secretase inhibitors," <i>Drug Discovery Today</i> , 5(8):316-317 (2000).
AZ11	Rotella, D. P., "Fenchylamine Sulfonamide Inhibitors of Amyloid $\beta$ Peptide Production by the $\gamma$ -Secretase Proteolytic Pathway: Potential Small Molecule Therapeutic Agents for the Treatment of Alzheimer's Disease," <i>Chemtracts - Organic Chemistry</i> 13:626-629 (2000).
AR12	Howlett, D. R. et al., "In search of an enzyme: the $\beta$ -secretase of Alzheimer's disease is an aspartic proteinase," <i>Trends Neurosci.</i> 23:565-570 (2000)
AS12	Ghosh, A. K. et al., "Structure-Based Design: Potent Inhibitors of Human Brain Memapsin 2 ( $\beta$ -Secretase)," <i>J. Med. Chem.</i> 44:2865-2868 (2001).

EXAMINER

DATE CONSIDERED